IngredientesNames and synonyms: Methylcobalamin (mecobalamin, MeCbl, or MeB12) is a cobalamin — a form of vitamin B12. It differs from cyanocobalamin in that the cyano group at the cobalt is replaced with a methyl group. Methylcobalamin features an octahedral cobalt(III) centre and can be obtained as bright red crystals; from the perspective of coordination chemistry, it is notable as a rare example of a compound that contains metal–alkyl bonds.
Molecular structure: The molecule contains a corrin tetrapyrrole ring with a cobalt atom at its center. Cobalt has six coordination sites, four of which bind to the nitrogen atoms of the pyrrole groups, while a fifth site associates with a "nucleotide" formed by 5,6-dimethylbenzimidazole, ribose, phosphate, and aminopropanol — also attached to a side chain of corrin. The derivative methylcobalamin functions as a coenzyme; it has a methyl group in the sixth coordination site of cobalt. It has a molecular formula of C₆₃H₉₁CoN₁₃O₁₄P with a molecular weight of 1344.8 g/mol.
Relation to other cobalamins: Cyano- and hydroxocobalamin are considered the storage or transport forms of cobalamin, while methylcobalamin and deoxyadenosylcobalamin are the active forms involved in enzymatic reactions. Hydroxycobalamin is produced by bacteria, and cyanocobalamin is a form derived during the purification of hydroxycobalamin for therapeutic or supplementation purposes. Both are further metabolized in the body to form the active forms, adenosylcobalamin and methylcobalamin. Cyanocobalamin does not occur in nature; it is artificially synthesized by the introduction of the cyanide group into hydroxocobalamin, which has been sourced from bacteria.
Natural sources: Investigation of the form of vitamin B12 in human blood plasma revealed, as the major component, a factor besides coenzyme B12 and traces of hydroxo- and cyanocobalamin. This factor was also found in liver, E. coli, and Streptomyces rimosus; evidence identified this analogue as methylcobalamin. Methylcobalamin is found in food and can also be artificially produced by bacteria. It predominates in blood plasma and certain other body fluids, such as cerebrospinal fluid, and in cellular cytosol. Methylcobalamin has been identified in Chlorella vulgaris. Since only bacteria and some archaea possess the genes and enzymes necessary to synthesize vitamin B12, plant and algae sources all obtain the vitamin secondarily from symbiosis with various species of bacteria, or in the case of fermented plant foods, from bacterial fermentation.
Commercial production: Commercial forms of methylcobalamin are produced in the laboratory through the conversion of cyanocobalamin. Methylcobalamin can also be produced in the laboratory by reducing cyanocobalamin with sodium borohydride in alkaline solution, followed by the addition of methyl iodide.
Methylcobalamin as a discrete molecule was not known to traditional medicine because it was not chemically characterized until the twentieth century. Its history is therefore inseparable from the broader story of vitamin B12 research, within which its identity and specific properties were progressively unraveled.
Early empirical work on the structure and function of cobalamins as coenzymes was conducted using vitamin B12-dependent bacteria in the 1950s. Prior to this, Addison anemia (pernicious anemia) had been described and the involvement of intrinsic factor was recognized through experiments involving regurgitated raw meat. The discovery of liver as a treatment for pernicious anemia in the 1920s led to the Nobel Prize in Medicine, and in 1948 Karl Folkers and Alexander Todd identified cobalamin as the active principle in liver.
Methylcobalamin was identified in natural source material and found in human blood plasma in the early 1960s. It had been prepared by partial synthesis a couple of years earlier and was shown to be active in the enzymatic synthesis of methionine, but had not previously been shown to occur naturally prior to Lindstrand's 1964 report in Nature.
Vitamin B12 had been used as a form of sports nutrition and employed to keep older people from developing anemia in earlier years. Vitamin B12 was also regarded as a "painkilling vitamin" in some countries from the 1950s. As methylcobalamin became recognized as the biologically active plasma form of B12, it was progressively adopted into clinical and supplemental use, particularly in Japan, where it became an approved prescription medication for peripheral neuropathies.
Methylcobalamin is itself the active constituent; it is not a botanical extract containing multiple phytochemicals. Its biological activity derives from its unique chemical properties as a cobalamin vitamer.
Cobalamin refers to a group of complex, chemically related co-factors characterized by a corrinic ring structure — a cobalt atom bound to six ligands — with similar biological activity. The upper (or β-axial) ligand varies and defines the vitamer of vitamin B12 (cyano, hydroxo, aquo, methyl, sulfito, nitrite, glutathionyl, or adenosyl group). The bioactive forms of the vitamin are methylcobalamin and 5′-deoxyadenosylcobalamin.
Methylcobalamin, along with adenosylcobalamin, is one of two active coenzymes used by vitamin B12-dependent enzymes, and it is the specific vitamin B12 form used by 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), also known as methionine synthase. Methionine synthase catalyzes the transfer of a methyl group from bound methylcobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. The cofactor is then remethylated by methyltetrahydrofolate.
In the form of methylcobalamin, the vitamin assists in the transfer of methyl groups from the folate derivative 5-methyltetrahydrofolate to the sulfur amino acid homocysteine to produce methionine in a cytosolic reaction catalyzed by methionine synthase. When vitamin B12 status is suboptimal or deficient, this reaction is inhibited, and homocysteine accumulates.
In humans, methionine synthase activity is important for preventing elevated homocysteine levels, which are linked to increased risk of cardiovascular diseases and neural tube defects during embryonic development. Additionally, methionine synthase activity is essential for regenerating tetrahydrofolate for one-carbon metabolism, which supports critical processes such as nucleotide biosynthesis in dividing cells.
In the form of methyl-B12, it assists in folate-dependent conversion of homocysteine to methionine catalyzed by methionine synthase. In the form of adenosyl-B12, the vitamin assists in the conversion of methylmalonyl-CoA to succinyl-CoA as an intermediate step in odd-chain fatty acid oxidation and ketogenic amino acid catabolism. When vitamin B12 is deficient, homocysteine and methylmalonic acid accumulate in the cell and are exported into the blood; thus, elevations in these compounds in plasma or serum are functional indicators of vitamin B12 deficiency.
Methylcobalamin that is ingested is not used directly as a cofactor, but is first converted by MMACHC into cob(II)alamin. Cob(II)alamin is then later converted into the other two forms, adenosylcobalamin and methylcobalamin, for use as cofactors. That is, methylcobalamin is first dealkylated and then regenerated.
Methylcobalamin participates in the Wood–Ljungdahl pathway, by which some organisms utilize carbon dioxide as their source of organic compounds. In this pathway, methylcobalamin provides the methyl group that couples to carbon monoxide (derived from CO₂) to afford acetyl-CoA — a derivative of acetic acid that is converted to more complex molecules as required by the organism. Methylcobalamin is produced by some bacteria and plays an important role in the environment, where it is responsible for the biomethylation of certain heavy metals; for example, the highly toxic methylmercury is produced by the action of methylcobalamin.
Methylcobalamin is equivalent physiologically to vitamin B12, and can be used to prevent or treat pathology arising from a lack of vitamin B12 intake (vitamin B12 deficiency). Methylcobalamin is considered to be equivalent in efficacy to the other vitamin B12 vitamers as a dietary supplement, with no clear evidence of differing efficacy between them.
Methylcobalamin and 5-deoxyadenosylcobalamin are the metabolically active forms of vitamin B12. The most common form of vitamin B12 in dietary supplements is cyanocobalamin. Other forms of vitamin B12 in supplements include adenosylcobalamin, methylcobalamin, and hydroxycobalamin. No evidence indicates that absorption rates of vitamin B12 in supplements vary by form of the vitamin.
A 2025 clinical study examined sublingual methylcobalamin in the treatment of childhood vitamin B12 deficiency. A total of 312 patients with vitamin B12 deficiency were divided into two groups: intramuscular cyanocobalamin (Group 1, n=29) and sublingual methylcobalamin (Group 2, n=283). The sublingual methylcobalamin protocol consisted of 1 puff (500 µg) daily for children under 8 years and 2 puffs (1000 µg) daily for those 8 years and older, administered for 1.5 months and then three times weekly for an additional 1.5 months. There were no significant between-group differences; both groups showed a statistically significant increase in levels above 300 ng/L. Sublingual methylcobalamin, a noninvasive treatment option, was as effective as intramuscular cyanocobalamin.
Vitamin B12 deficiency is a clinically important condition associated with several metabolic disorders such as megaloblastic anemia, hyperhomocysteinemia, and cardiovascular, cerebrovascular, and neurological disorders; thus, optimal intake is important. Deficiency occurs when B12 stores are depleted due to inadequate dietary intake or impaired absorption.
Diabetic peripheral neuropathy (DPN) represents one of the most extensively studied clinical applications of methylcobalamin. Multiple randomized controlled trials and systematic reviews have examined this area.
One double-blind study of methylcobalamin in patients with diabetic neuropathy showed that the active group demonstrated statistical improvement in somatic and autonomic symptoms, with regression of signs of diabetic neuropathy. Motor and sensory nerve conduction studies showed no statistical improvement after 4 months. The drug was easily tolerated by the patients and no side effects were encountered.
Oral supplementation with methylcobalamin (1,500 µg daily for 24 weeks) in individuals with diabetes has been demonstrated to improve tingling, upper limb symptoms, ataxia, signs of impaired position sense, vibration sense, pinprick sensation, and knee reflexes. These reports noted improvement in diabetic neuropathy without documenting baseline B12 levels; therefore, it is reasonable to assume that the neuropathy that responded to B12 supplementation could have been, at least in part, B12 deficiency neuropathy rather than diabetic neuropathy.
A randomized, double-blind, placebo-controlled trial concluded that the treatment of metformin-treated patients with diabetic neuropathy with 1 mg of oral methylcobalamin for twelve months improved plasma B12 levels and improved all neurophysiological symptoms.
A 2025 systematic review and meta-analysis in Frontiers in Endocrinology examined the combination of dapagliflozin (an SGLT-2 inhibitor) and methylcobalamin for DPN. Dapagliflozin and methylcobalamin, the active form of vitamin B12, have both demonstrated potential in managing DPN; the systematic review assessed the efficacy and safety of their combined use, synthesizing findings from multiple randomized controlled trials.
Animal evidence provides a mechanistic context: Methylcobalamin has a special affinity for nerve tissues, promoting myelination and transport of axonal cytoskeleton. In streptozotocin-induced diabetic rats, untreated animals developed significant delay of nerve conduction velocity, and methylcobalamin treatment normalized that velocity. Methylcobalamin treatment in diabetic rats delayed the reduction in sciatic nerve IGF-1 content, consistent with retardation in nerve velocity conduction and structural impairment. No effect of methylcobalamin on blood glucose was shown; methylcobalamin was concluded to delay onset of diabetic peripheral neuropathy via up-regulation of neural IGF-1 gene expression.
Evidence strength assessment: The clinical evidence for methylcobalamin in DPN is moderate, supported by multiple randomized trials. However, a recognized limitation is that many studies did not document baseline B12 levels, making it unclear whether benefits reflect correction of B12 deficiency rather than a specific pharmacological effect on diabetic nerve disease.
Methylcobalamin has been used to treat some nutritional diseases and other conditions. As an auxiliary agent, it exerts neuronal protection by promoting regeneration of injured nerves and antagonizing glutamate-induced neurotoxicity. Several lines of evidence have demonstrated that methylcobalamin may have potential analgesic effects in experimental and clinical studies. For example, it alleviated pain behaviors in diabetic neuropathy, low back pain, and neuralgia. Methylcobalamin improved nerve conduction, promoted the regeneration of injured nerves, and inhibited ectopic spontaneous discharges of injured primary sensory neurons.
As an auxiliary agent, methylcobalamin exerts neuronal protection by promoting regeneration of injured nerves and antagonizing glutamate-induced neurotoxicity. Several lines of evidence have demonstrated that methylcobalamin may have potential analgesic effects in experimental and clinical studies; for example, it alleviated pain behaviors in diabetic neuropathy, low back pain, and neuralgia.
Evidence strength assessment: Evidence for specific analgesic properties of methylcobalamin is preliminary to moderate. In vitro and animal data are more robust; human clinical trials in pain conditions are present but generally smaller and methodologically heterogeneous. A 2013 review in Neural Plasticity (PMC3888748) characterized this as an emerging area warranting further investigation.
Methylcobalamin at ultra-high doses (far exceeding nutritional supplement ranges) has been extensively studied in ALS through a program of Japanese clinical trials.
A phase II/III randomized controlled study evaluated the efficacy and safety of intramuscular ultra-high-dose methylcobalamin in patients with ALS. 373 patients with ALS were randomly assigned to placebo, 25 mg, or 50 mg of methylcobalamin groups. The primary endpoints were the time interval to primary events (death or full ventilation support) and changes in the Revised ALS Functional Rating Scale (ALSFRS-R) score from baseline to week 182. No significant differences were detected in either primary endpoint. However, post-hoc analyses of methylcobalamin-treated patients diagnosed and entered early (≤12 months' duration) showed longer time intervals to the primary event and less decrease in the ALSFRS-R score than the placebo group (p<0.025). Although ultra-high-dose methylcobalamin did not show significant efficacy in the whole cohort, this treatment may prolong survival and retard symptomatic progression without major side effects if started early.
Based on this phase II/III signal, a dedicated phase 3 trial (JETALS) was conducted. This was a multicenter, placebo-controlled, double-blind, randomized phase 3 clinical trial with a 12-week observation period and 16-week randomized period, conducted from October 17, 2017, to September 30, 2019. Patients were recruited from 25 neurology centers in Japan. 130 patients with ALS were enrolled, divided equally into the treatment group receiving an ultrahigh dose (50 mg) of methylcobalamin and the placebo group; 126 completed the trial with 124 continuing to the open-label extended trial period. The changes in ALSFRS-R score were −2.66 with methylcobalamin versus −4.63 with placebo during the 16-week treatment period, a statistically significant difference.
The most recent phase 3 trial (JETALS) of ultra-high dose methylcobalamin demonstrated significant slowing of ALSFRS-R changes (0.5/month), with marked reduction of serum homocysteine levels in the initial double-blind period. Ultra-high dose methylcobalamin at these doses is not a vitamin supplement but a novel disease-modifying therapy for ALS, and it emphasizes homocysteine as a key factor in the disease process.
A vitamin B12 analogue, methylcobalamin, has a protective effect on cultured cortical neurons against glutamate-induced cytotoxicity. Ultra-high-dose methylcobalamin (25 mg/day i.m.) was shown to slow down the progressive reduction of compound muscle action potential (CMAP) amplitudes in ALS in the short term (4 weeks).
As the drug was only tested on participants early in the disease process, it is not clear whether the treatment would be appropriate for participants with more advanced disease. Methylcobalamin treatment results in a marked change in urine colour, which could mean that participants may have known whether they were receiving placebo or methylcobalamin, potentially influencing results.
Evidence strength assessment: The phase 3 JETALS trial is the strongest evidence in this area, demonstrating statistically significant slowing of functional decline in early-stage ALS. However, the study was conducted exclusively in Japan, results were significant only in the early-stage subgroup in the prior phase II/III, blinding integrity is questionable due to urine discolouration, and the doses used (50 mg twice weekly by intramuscular injection) are orders of magnitude above dietary supplement doses. As of 2024, the drug was pending approval in Japan.
Methylcobalamin has been reported to enhance the light sensitivity of the circadian clock and to improve the quality of sleep. It has been suggested that methylcobalamin does not impact total levels of cortisol, but rather helps shift the cortisol secretion peak, helping place the cortisol clock back on schedule.
The therapeutic effect of methylcobalamin on sleep–wake rhythm disorders was examined in a double-blind trial. In the group given a large dosage, a higher percentage of improvement was found compared to the control group with a small dosage, although the difference was not significant. The test group inconsistently showed significant improvement in both sleep–wake cycle parameters and clinical symptoms. However, because the percentage of improvement was low and significant improvement was inconsistent, methylcobalamin might be considered to have a low therapeutic potency and possible use as a booster for other treatment methods of the disorders.
With no further research available at the moment, there is insufficient evidence to recommend B12 for sleep rhythm disorders.
Evidence strength assessment: Evidence in this area is weak. The biological plausibility is established through circadian mechanism research, but human trials have produced inconsistent results, and current evidence does not support clinical recommendation of methylcobalamin as a primary treatment for sleep–wake rhythm disorders.
Methylcobalamin has neuronal protection properties, including promoting injured nerve and axonal regeneration and confronting glutamate-induced neurotoxicity. Methylcobalamin improved nerve conduction in patients with diabetic neuropathy and in streptozotocin-diabetic and acrylamide-neuropathy animal models.
Methylcobalamin has an outstanding effect on improving neuronal conduction. Preclinical research has explored methylcobalamin in vincristine-induced peripheral neuropathy (VIPN): a preclinical experiment investigating the preventive effect of methylcobalamin on VIPN revealed that methylcobalamin could ameliorate mechanical allodynia and thermal hyperalgesia by inhibiting mitochondrial damage and intraepidermal nerve fibre loss in a rat model of VIPN.
Evidence strength assessment: Neuroprotective and nerve-regenerative effects are well-established in animal and in vitro models. Translational human evidence is more limited and predominantly comes from studies in diabetic neuropathy. Extrapolation to other nerve injury etiologies should be made cautiously, as human evidence for these broader indications remains preliminary.
Methionine synthase catalyzes the final step in the regeneration of methionine from homocysteine. Mutations in the MTR gene have been identified as the underlying cause of methylcobalamin deficiency, which can result in elevated levels of homocysteine (hyperhomocysteinemia) — associated with blindness, neurological symptoms, and birth defects.
In humans, methionine synthase activity is important for preventing elevated homocysteine levels, which are linked to increased risk of cardiovascular diseases and neural tube defects during embryonic development. While methylcobalamin's mechanism directly supports homocysteine reduction, clinical trials showing that B12 supplementation reduces homocysteine have not consistently demonstrated a corresponding reduction in cardiovascular events — an important distinction between biochemical and clinical outcomes.
Commercially available oral dosage forms include capsules (2000 µg), lozenges (1 mg; 500 µg), chewable tablets (1000 µg; 2500 µg; 5000 µg), orally disintegrating tablets (1 mg; 5000 µg), and sublingual tablets (5000 µg).
The following doses have been reported in specific published clinical contexts:
Note on ALS doses versus dietary supplement doses: Ultra-high dose methylcobalamin in the ALS context is not a vitamin supplement but a novel disease-modifying therapy. The doses used in ALS trials (25–50 mg intramuscularly) are thousands of times higher than the nutritional reference values for vitamin B12.
Vitamin B12 has a long history of safe use even at high dosages. Methylcobalamin is generally considered safe when taken at recommended doses. Vitamin B12 is water-soluble, which means excess amounts are usually excreted in urine. Vitamin B12 at dosages found in foods or from supplements is well tolerated.
Gastrointestinal effects from methylcobalamin may include anorexia, diarrhea, headache, nausea, and vomiting. Side effects are rare but may include mild digestive upset, headache, or skin reactions at the injection site when given by injection. High doses of vitamin B12 (more than 5 to 10 mg/week) or long durations of use have been associated with worsening acne, particularly in females.
There is clear evidence that proton-pump inhibitors (PPIs), H2-receptor antagonists (H2RAs), and metformin can reduce serum vitamin B12 concentrations by inhibiting the absorption of the vitamin. Metformin is thought to decrease B12 levels by interfering with calcium-dependent binding of the B12–intrinsic factor complex to its receptor. The risk of metformin-induced B12 deficiency increases with dose and duration of metformin therapy. Since the typical amount of vitamin B12 stored in the liver is 2500 pg, it is believed that, in most cases, it will take at least five years of metformin use to deplete these reserves. However, other causes could increase the decrease of hepatic reserves, especially in the elderly due to the high prevalence of atrophic gastritis and proton pump inhibitor use.
Vitamin B12 supplements may interact with medications, and some medications, including gastric acid inhibitors and metformin, may affect vitamin B12 levels. Vitamin B12 supplements have the potential to interact with certain medications. There is clear evidence that proton-pump inhibitors (PPIs), H2-receptor antagonists (H2RAs), and metformin can reduce serum vitamin B12 concentrations by inhibiting absorption of the vitamin. However, it is unclear whether the effects of these drugs on serum vitamin B12 are associated with increased risk of biochemical or functional deficiency or clinical deficiency (including megaloblastic anemia and neurologic disorders such as peripheral neuropathy and cognitive dysfunction).
People with certain medical conditions, such as kidney disease or Leber's hereditary optic neuropathy, should discuss methylcobalamin use with a healthcare professional before starting supplements. Specific dedicated toxicological studies for methylcobalamin are lacking. The prevalence of vitamin B12 deficiency in elderly populations is 20–40%; elderly patients are additionally vulnerable due to frequent concomitant use of other agents such as H2 blockers, antacids, and diuretics that may independently impair absorption, alongside higher burden of chronic illness.
Methylcobalamin treatment at high doses results in a marked change in urine colour, which could mean that participants in clinical trials may have known whether they were receiving placebo or methylcobalamin, potentially influencing results (including a potential "nocebo" effect).
Condiciones de salud que Metilcobalamina puede ayudar a apoyar.
Ultra-high-dose MeCbl has been investigated as a disease-modifying therapy for ALS across multiple clinical trials in Japan. The Phase III JETALS trial showed a significant 43% reduction in ALSFRS-R score decline in early-stage patients. MeCbl received regulatory approval in Japan for ALS in 2024 following JETALS results.
MeCbl is an established treatment for megaloblastic anemia arising from vitamin B12 deficiency. It is a required coenzyme for DNA synthesis in hematopoietic cells; deficiency leads to impaired red blood cell maturation and macrocytic anemia. MeCbl is approved and used clinically in Japan for megaloblastic anemia.
MeCbl contributes to arterial health through its role in homocysteine clearance. Excess homocysteine directly injures endothelial cells, promotes LDL oxidation, and has prothrombotic effects. Clinical and biochemical evidence links B12-mediated homocysteine lowering with improved endothelial function and reduced atherosclerotic risk.
Methylcobalamin, the active coenzyme form of vitamin B12, was evaluated in a randomized controlled trial of 60 Bell's palsy patients. Those treated with methylcobalamin alone achieved complete facial nerve recovery in a mean of ~2 weeks, compared to ~9.6 weeks for the steroid-only group. The results were statistically significant (p<0.001), supporting its role in accelerating peripheral nerve regeneration.
Methylcobalamin is the neurologically active coenzyme form of vitamin B12. B12 deficiency causes demyelination, elevated homocysteine, and cognitive impairment presenting as brain fog. A study in 202 patients with cognitive impairment and low/deficient B12 found supplementation improved cognition in 84% and memory/attention scores in 78%. Methylcobalamin is the preferred form for neurological applications.
Methylcobalamin is the neurologically active form of vitamin B12 and has been specifically used in CTS multi-ingredient supplement formulas demonstrating improved nerve function and recovery. It promotes peripheral nerve regeneration, reduces neuropathic pain, and is included in validated clinical formulas for CTS perioperative support and conservative management.
Methylcobalamin (vitamin B12, active coenzyme form) is required for methionine synthase activity and methylation reactions supporting connective tissue matrix synthesis. Vitamin B12 deficiency is associated with elevated homocysteine, which directly degrades cartilage through MMP-mediated mechanisms. Clinical studies link homocysteine reduction (via B12/folate) with improved OA and joint outcomes, and methylcobalamin combined with folate has been shown to reduce cartilage degradation biomarkers (CTX-II) in OA patients.
MeCbl participates in the methylation cycle and supports mitochondrial function indirectly through homocysteine-methionine metabolism and one-carbon metabolism, which feeds into the TCA cycle via succinyl-CoA production. B12 deficiency impairs cellular energy metabolism and is associated with fatigue and weakness.
Methylcobalamin is the active coenzyme form of vitamin B12 increasingly used in children's MVMs for superior neurological bioavailability compared to cyanocobalamin. It participates directly in methionine synthesis and neurological repair without requiring additional metabolic conversion. Multiple peer-reviewed pediatric nutritional composition patents list it as a preferred B12 form.
B12 deficiency, corrected by MeCbl, is a well-established cause of fatigue, weakness, and low energy. MeCbl repletion in deficient individuals restores energy and reduces fatigue. Some clinical evidence also suggests B12 may have effects on fatigue beyond nutritional deficiency correction, possibly via circadian or neurological mechanisms.
Methylcobalamin (MeCbl) has documented analgesic effects in several clinical contexts, including diabetic neuropathic pain, herpetic neuralgia, and low back pain. It promotes nerve regeneration and reduces peripheral sensitization via NF-κB modulation. Multiple randomized controlled trials and a meta-analysis support its use, though evidence quality is variable.
MeCbl has been studied in the context of circadian rhythm disorders, with human and animal data showing it can phase-advance the melatonin rhythm and enhance light-induced circadian phase shifts. Clinical use in delayed sleep phase disorder (DSPD) and non-24-hour sleep-wake syndrome has been investigated. Effects appear to involve facilitation of melatonin synthesis in the pineal gland.
Observational and interventional evidence links vitamin B12 status—particularly MeCbl—to cognitive aging. B12 deficiency is associated with accelerated cognitive decline, brain atrophy, and elevated homocysteine. MeCbl is mechanistically implicated via myelin maintenance, methylation, and homocysteine clearance. RCT evidence is mixed but selected trials in high-risk groups show slowing of brain atrophy.
B12 deficiency is associated with depression and neuropsychiatric symptoms, with MeCbl mechanistically linked via neurotransmitter synthesis, methylation, and homocysteine metabolism. B12 deficiency has been linked to increased prevalence of depression in observational studies. MeCbl supports serotonin and dopamine synthesis relevant to mood regulation.
Cobalamin, particularly via MeCbl, plays a role in male reproductive function. Studies show significantly lower seminal plasma cobalamin concentrations in azoospermic men versus normozoospermic men. A clinical trial found that 1,500 mcg/day of methylcobalamin for 4–24 weeks resulted in improvements in sperm parameters in infertile males, though the study had methodological limitations.
MeCbl is mechanistically linked to cognitive function including focus and concentration via its roles in neurotransmitter synthesis, myelin integrity, and methylation reactions in the brain. Deficiency produces well-documented cognitive impairments including difficulty concentrating. Clinical studies in autism have shown improved cognitive domains with MeCbl supplementation.
MeCbl deficiency, particularly in the context of inborn errors of cobalamin metabolism, is associated with significant retinal degeneration, macular atrophy, and visual loss. Cobalamin therapy (including MeCbl-related pathways) is used to manage ocular features of cblC disease. Optic neuropathy is also a recognized manifestation of B12 deficiency.
Methylcobalamin is the active, neurologically available form of vitamin B12 that directly participates in methionine synthesis and DNA methylation. It is preferred over cyanocobalamin for neurological protection in aging due to superior CNS penetration and activity without requiring metabolic conversion. Multiple studies confirm methylcobalamin supplementation protects neurons and supports cognitive aging.
MeCbl is essential for normal growth and development, particularly neurodevelopment. Deficiency during fetal life and infancy impairs myelination, synaptogenesis, DNA methylation, and hematopoiesis. Severe early-onset cobalamin deficiency causes failure to thrive, developmental delay, and feeding difficulties.
Methylcobalamin is the bioactive, neurologically active form of vitamin B12, specifically recommended for hearing health applications over cyanocobalamin. Low serum vitamin B12 is significantly associated with age-related hearing loss and tinnitus. B12 deficiency causes degeneration of cochlear nerve neurons. Methylcobalamin specifically appears in clinical hearing supplement formulas referenced by ConsumerLab and NIH-associated practitioners.
MeCbl lowers homocysteine—an independent cardiovascular risk factor—by acting as cofactor for methionine synthase. Randomized controlled evidence supports homocysteine reduction with methylcobalamin-containing B-vitamin formulations. However, lowering homocysteine has not been definitively shown to reduce hard cardiovascular endpoints in all populations.
Methylcobalamin is the biologically active coenzyme form of vitamin B12 that directly participates in the methionine synthase reaction, converting homocysteine to methionine. It donates a methyl group to homocysteine via the 5-MTHF–methionine synthase pathway, making it directly effective for homocysteine lowering without requiring metabolic activation.
Methylcobalamin is the bioactive, neurologically active form of vitamin B12 and is the preferred supplemental form for Hashimoto's patients with B12 deficiency, particularly where neurological symptoms are present. B12 deficiency is prevalent in 27% of hypothyroid patients and is compounded by autoimmune gastric involvement in Hashimoto's. Methylcobalamin bypasses the need for conversion from cyanocobalamin.
Methylcobalamin (the active coenzyme form of vitamin B12) has been studied in multiple human trials for its effects on circadian rhythm phase-shifting and melatonin regulation. A crossover study found oral methylcobalamin (3 mg/day) significantly phase-advanced the 24-hour melatonin rhythm by approximately 1.1 hours versus placebo and enhanced light-sensitivity of the circadian clock. Another trial showed intravenous methylcobalamin increased daytime alertness and body temperature rhythms, suggesting a clock-modulating effect. These properties have led to its investigation and use for circadian rhythm sleep-wake disorders including jet lag type.
Methylcobalamin is the neurologically active form of vitamin B12 that directly supports myelin synthesis and neuronal function. It is preferentially accumulated in brain tissue and used in Japan as a prescription drug for peripheral neuropathy and cognitive support. Evidence supports its role in maintaining cognitive function, particularly in B12-deficient individuals.
Methylcobalamin is the bioactive, neurologically active form of vitamin B12 used directly for myelin synthesis, neuronal repair, and homocysteine regulation. It is the preferred B12 form for cognitive and neurological applications. Deficiency causes progressive memory impairment and dementia, and clinical studies in deficient and elderly populations show memory improvements with methylcobalamin repletion.
Methylcobalamin is the active, neuroavailable form of vitamin B12, directly supporting myelin integrity, neurological function, and neurotransmitter synthesis. It is used clinically in nerve repair and to restore mental energy and clarity in B12-deficient individuals.
Methylcobalamin is the active coenzyme form of vitamin B12 that directly participates in the remethylation of homocysteine to methionine via methionine synthase (MTR). It is a key cofactor in the methionine cycle and supplies methyl groups for SAMe regeneration. Clinical RCTs confirm it lowers elevated homocysteine, the primary biomarker of impaired methylation.
Methylcobalamin is the neurologically active, methylated form of vitamin B12 that participates in methionine synthase reactions supporting mitochondrial one-carbon metabolism and myelin integrity. It is used in mitochondrial neuropathy management and mitochondrial disorder supplementation protocols when the mitochondrial methylmalonyl-CoA pathway is impaired.
Methylcobalamin is the active, neurologically bioavailable form of vitamin B12 that promotes regeneration of injured nerves, antagonizes glutamate-induced neurotoxicity, and improves nerve conduction. Clinical studies document its analgesic effects in diabetic neuropathy, low back pain, and neuralgia.
Methylcobalamin is the bioactive coenzyme form of vitamin B12 that directly participates in nerve tissue metabolism without requiring hepatic conversion, making it the preferred form for neuropathy applications. RCTs demonstrate that methylcobalamin significantly improves nerve conduction velocity and reduces pain in diabetic peripheral neuropathy. Animal studies show ultra-high dose methylcobalamin promotes nerve regeneration by upregulating gene transcription and protein synthesis in peripheral nerve fibers.
MeCbl promotes neuroplasticity through mechanisms including axonal regeneration, neurite outgrowth, promotion of BDNF secretion, and support of the methylation cycle required for synaptic plasticity and gene expression regulation. Both experimental and clinical data support MeCbl's role in neural repair and adaptive remodeling.
Methylcobalamin is the neurologically active form of vitamin B12 that directly regenerates SAMe supporting serotonin, dopamine, and norepinephrine biosynthesis. It accumulates in brain tissue better than cyanocobalamin and directly participates in methionine synthase reactions. Japanese clinical studies confirm its role in CNS function and circadian neurotransmitter regulation.
The neurologically active form of vitamin B12, methylcobalamin supports post-illness neurological recovery, immune cell DNA synthesis, and energy metabolism. It has superior blood-brain barrier penetration compared to cyanocobalamin and is used in post-illness peripheral neuropathy and fatigue recovery.
Methylcobalamin is the neurologically active form of vitamin B12 that directly supports myelin synthesis and neurological recovery, particularly relevant to post-viral neuropathy and brain fog. Deficiency is documented in long COVID patients. Methylcobalamin is preferred in post-viral neurological recovery protocols for its superior CNS bioavailability versus cyanocobalamin.
Methylcobalamin is the active, bioavailable form of vitamin B12 required for neurological repair, energy metabolism, and homocysteine clearance postpartum. It is secreted into breast milk, depleting maternal stores during lactation. A 2025 PMC systematic review links low B12 to elevated postpartum depression risk, and methylcobalamin is the preferred supplemental form in evidence-based postnatal formulas.
Adequate MeCbl (as the active form of B12) is essential during pregnancy for fetal brain development, myelination, DNA methylation, and prevention of neural tube defects. Maternal B12 deficiency is associated with impaired placental development, adverse neurodevelopmental outcomes in offspring, and megaloblastic anemia. MeCbl has been used prenatally in cases of maternal cobalamin metabolic defects.
MeCbl is used as an adjunct in rheumatoid arthritis (RA), where hyperhomocysteinemia—partly driven by B12 deficiency—contributes to both disease activity and increased cardiovascular risk. MeCbl lowers homocysteine in RA patients. It has also been cited in PMC literature as a condition where MeCbl has clinical use beyond its nutritional role.
Sistemas corporales que Metilcobalamina puede ayudar a apoyar.
Volver